New drive-through Burger King set to create 84 jobs
PLANS for a drive-through Burger King in Brynmawr have been given the green light by councillors despite objectors arguing that it will be bad for people's health.
At a meeting of Blaenau Gwent County Borough Council's Planning committee on Thursday, June 5 councillors received a planning application by Starburst limited for a drive through Burger King, a pizza restaurant/takeaway, and a tanning 'shop' on land at Blaina Road in Brynmawr.
The development could create 84 full and part time jobs,
Planning officer Joanne White explained that outline planning permission had been granted in 2018 for a nearby Costa Coffee drive through which also included building 25 houses on the site.
Ms White said: 'But the residential part of the permission has never been implemented and has since lapsed.'
Bid to turn building back into a pub falls short in planning appeal
Long-running neighbour dispute over access to a lane finally resolved
She believed it would be 'unlikely' that a housing scheme would ever be built there and recommended that councillors approve the plans.
Cllr Jules Gardner (Labour) one of the county councillors for Brynmawr spoke against the proposal and said that he and his fellow ward councillors had received a 'plethora' of complaints from people against the proposal.
Cllr Gardner said: 'This project will provide no new experiences or facilities but offers purely a duplication of existing services, more fast food outlets, another burger bar and pizza parlour only 100 metres from an existing drive-through McDonalds.'
He added that the development could also cause more antisocial behaviour, traffic congestion and have a detrimental impact on the town centre.
Objector Chris Nottingham said: 'The proposal would undermine our collective efforts to improve population health and in particular children's in Blaenau Gwent.
'Our local stats are shocking, over a quarter of our children are overweight or obese.
'The top six diseases for general population in Blaenau Gwent are all linked to poor diet in particular type-2 diabetes cardio-vascular disease and certain cancers.
He believed planning policy 'can' be used to support improving health.
Mr Nottingham said: 'We cannot do this by allowing the clustering of fast food takeaways especially near schools and areas with high deprivation.
'We're way above the average for fast food density and this is not by accident, the business model exploits the economic vulnerabilities of communities and deepens health inequalities.'
The meeting was then opened up to comments and questions from committee members.
Cllr George Humphreys (non-aligned – Independent) asked: 'What support would be put in place to help and support the added pressures on local doctors and health service due to this.'
Development management team manager Steph Hopkins said: 'It would be unfair to assume that this development is going to have a direct impact on the health service.
'I don't think we would be looking for a financial contribution here to put towards health services.'
Cllr David Wilkshire (Labour) said: 'It's a difficult one for planning but we have to consider the health of the community in general.'
'There's lots of things that could be developed on that site which could be more useful to the community.'
With the belief that the development would cause extra traffic congestion Cllr Wilkshire believed this would 'add another burden' on the town and he would vote against it.
Mrs Hopkins stressed: 'There's been ample opportunity over the years for the market to come forward with alternatives including housing.
'Clearly this site has not been an attractive proposition.'
'There are no local or national policies which restricts the provision of fast food takeaways.
'It's not the function of planning policy to dictate consumer choice.
'Consuming food from a fast food restaurant can form part of a balanced diet in moderation, there are also healthier options provided these days.'
She added that people also have the choice of walking or cycling there.
The committee then went to a vote which saw four councillors vote in favour of the proposal and two against.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Cardiac Risk Warning for Lamotrigine Challenged
Real-world data from two new studies showed no increased risk for cardiac issues in older adults with epilepsy taking the antiseizure medication (ASM) lamotrigine (Lamictal) vs levetiracetam. The findings add to growing evidence that may eventually lead the FDA to reconsider its current cardiac safety warning, researchers said. The FDA added the cardiac warning label in 2020 based on in vitro studies and case reports of arrhythmias in some patients with underlying heart disease who were taking the drug. However, as reported by Medscape Medical News at that time, several groups challenged the severity of the warning — particularly given that clinicians had been prescribing lamotrigine for three decades without the widespread evidence of such risks. The first new cohort study used data from US Medicare claims and UK claims for more than 53,00 total patients. Its findings showed no difference in new diagnoses of ventricular tachycardia/ventricular fibrillation (VT/VF) between patients initiating the use of lamotrigine and those initiating the use of levetiracetam. Results from the second cohort study, which used Medicare data of nearly 12,000 new lamotrigine users and nearly 150,000 new levetiracetam users, showed no significant between-group differences in incidence of ventricular arrhythmia and sudden cardiac arrest (VA/SCA). The study was prompted by the FDA's safety warning, which was based on limited evidence, lead author Gloria Y.F. Ho, PhD, told Medscape Medical News . 'Our study was done in people, had a comparator, and also looked at several subgroups. And we did not find an increased risk' for cardiac outcomes, said Ho, visiting scholar at the Center for Pharmacoepidemiology and Treatment Science at Rutgers University, New Brunswick, New Jersey. The findings for both studies were published online on June 11 in Neurology . Closing the Evidence Gap Lamictal accounts for 'about 10% of all antiseizure medication use,' the investigators noted in a press release. It remains first-line therapy for certain forms of epilepsy, according to the American Epilepsy Society (AES) and the American Academy of Neurology. The drug inhibits voltage-gated sodium channels, which is a mechanism also implicated in regulating cardiomyocyte excitability. In October 2020, the FDA updated the lamotrigine label to warn about its potential to prolong QT interval, induce new arrhythmias, and slow ventricular conduction in patients with structural or functional heart disease on the basis of an in vitro electrophysiologic study and some case reports. In addition, rodent studies have shown prolonged QT interval time with high-dose lamotrigine vs placebo or a low dose of the drug. 'However, it is uncertain whether these findings are applicable to human physiology,' Ho and colleagues wrote. They added that other studies have often been underpowered to detect rare outcome risks. 'In such instances, real-world data sources can help provide valuable insights to fill this gap,' they noted. Class III Evidence In the first study, led by Samuel W. Terman, MD, from the Department of Clinical Neurosciences at the University of Calgary, Calgary, Alberta, Canada, participants were included if they had filled their first ASM prescription following a first seizure or epilepsy diagnosis, with no prescriptions for this drug class in the previous year. The full patient population included 40,554 patients from Medicare (3038 lamotrigine users and 37,516 levetiracetam users) and 13,098 patients from the UK Clinical Practice Research Datalink (CPRD; 8694 lamotrigine users and 4404 levetiracetam users). In the Medicare group, the median age of those receiving lamotrigine vs levetiracetam was 61 vs 74 years. In the CPRD group, the median age was 34 vs 48 years. The adjusted hazard ratio (HR) for VT/VF was 0.73 for lamotrigine vs levetiracetam in the Medicare dataset and 0.75 for lamotrigine vs levetiracetam in the CPRD dataset. The cumulative incidences were 1.7% vs 2.3% and 0.2% vs 0.3%, respectively. In addition, lamotrigine showed a 'slightly, but nonsignificantly, lower 2-year absolute difference' in cumulative VT/VF incidence in both datasets, the researchers wrote. Sensitivity analyses assessing such things as atrial or any arrhythmias and existing cardiovascular diagnoses showed similar results. 'This study provides class III evidence that lamotrigine did not significantly increase the 2-year cumulative incidence of VT/VF in adult patients with epilepsy,' the investigators wrote. They added that the findings 'do not support concerns regarding lamotrigine increasing arrhythmias.' No Risk in Patients With Heart Disease Using 2007-2019 data of Medicare-insured patients with epilepsy and aged at least 65 years, Ho and her team assessed 11,786 new users of lamotrigine (mean age, 74 years; 64% women) and 147,130 new users of levetiracetam (mean age, 77 years; 60% women). Results showed similar incidence of VA/SCA between the two treatment groups (7 vs 8.2 per 1000 person-years; P =.15) and a nonsignificantly higher adjusted HR of 0.84 for the lamotrigine vs levetiracetam groups ( P =.13). The HRs for VA and SCA individually were similar at 0.86 and 0.83, respectively. Secondary analyses showed no increased risk for VA/SCA in lamotrigine vs levetiracetam users with a baseline history of cardiac conditions, such as heart disease or heart failure. However, lamotrigine users with a baseline history of arrhythmias had a significantly reduced risk for VA/SCA (HR, 0.51) and for the use of any antiarrhythmic drugs (HR, 0.67). The investigators noted that although 'it has been postulated that lamotrigine increases the risk for VA/SCA because of its pharmacodynamic properties,' this assertion was based on studies that did not include older at-risk adults, including those with a history of heart disease. The new findings 'do not support' the current FDA warning label, they added. 'Lamotrigine is a very common and effective drug. Because of the FDA warning, it may limit its use in people who could benefit from it. Because they have a history of heart disease, they may not be able to get the prescription and this could affect the clinical management of epilepsy,' Ho said. Still, she recommended that clinicians evaluate patients on a case by case basis. 'At the end of the day, people in this age group may have other comorbidities and may be taking other medications. So I cannot just say, 'This is safe. Go ahead and use it,'' she said. Ho also noted that the findings may not be generalizable to younger patients because they used Medicare data of individuals older than 65 years or generalizable to those without epilepsy because the drug is also prescribed as a mood stabilizer for bipolar disorder. Two Studies, Same Conclusion In an accompanying editorial, Leah J. Blank, MD/MPH, assistant professor of neurology at the Icahn School of Medicine at Mount Sinai, New York City, noted that both groups of investigators used real-world data and advanced analysis techniques to answer safety questions surrounding the drug. Although Blank pointed out both studies were observational and retrospective in nature, she wrote that the researchers accounted for all of that in their measures. 'Together, these data suggest that lamotrigine likely is safe in clinical practice and can continue to be used as an effective and well tolerated antiseizure medication,' Blank wrote. She also told Medscape Medical News that she prescribes the medication in her own practice. 'The studies were important because lamotrigine is an excellent antiseizure medication and it appears to be very well tolerated. Patients tend to like it and do well on it,' said Blank. 'It's reassuring that two different groups, using slightly different methods, came to the same conclusion that there is not an increased risk for cardiac events in people taking lamotrigine,' she said. Blank said it is worth noting that the human data do not support the FDA warning label. Asked whether it would be taking the new findings into consideration regarding its safety warning, a spokesperson for the FDA told Medscape Medical News that, in general, it does not comment on specific studies. Rather, the organization 'evaluates them as part of the body of evidence to further our understanding about a particular issue and assist in our mission to protect public health.' In addition, a representative for the AES told Medscape Medical News that the organization is not currently working on a statement based on these studies at this time.
Entrepreneur
3 hours ago
- Entrepreneur
Entrepreneur UK's London 100: DrDoctor
DrDoctor has become one of the most trusted healthtech partners to the NHS, transforming how millions of patients access and manage their care. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Industry: Healthcare Tom Whicher, CEO and founder of DrDoctor, is driving the shift to hybrid healthcare across the NHS – blending technology with human care. Under Tom's leadership, DrDoctor has become one of the most trusted healthtech partners to the NHS, transforming how millions of patients access and manage their care. Founded in 2012, the company connects fragmented systems across hospitals, community services, and patients to power a hybrid model. Today, DrDoctor manages over 140m appointments for 36m patients and is trusted by more than 70 NHS organisations, covering 64% of the country. It has delivered £100m of value to the health system in the UK. In 2024, Tom launched DrDoctor's Smart Centre, powered by AI – a set of pioneering products that predict which patients are most at risk of missing appointments and dynamically optimises clinic capacity through targeted, automated interventions. Early results have shown that Smart Centre reduces missed appointments by 30%. The team has grown by 45% over the past year to 146 people, fuelled by a £10m investment round led by YFM Equity Partners. With 2023 revenues exceeding £10m and a current valuation of £80m, DrDoctor is delivering both commercial success and system-level change against a backdrop of NHS reform.
Yahoo
5 hours ago
- Yahoo
AstraZeneca signs $5 billion research deal with China's CSPC
(Reuters) -AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under the agreement, the two companies will collaborate to discover and develop pre-clinical candidates for potential treatments targeting chronic diseases, with CSPC conducting AI-driven research in Shijiazhuang City. Cambridge, UK-based AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion in development milestones and $3.6 billion in sales-related milestones, AstraZeneca said. In March, AstraZeneca announced plans to invest $2.5 billion in a research and development hub in Beijing, as it works to rebuild trust in its second-largest market.
